Hosted on MSN14d
FDA grants breakthrough designation to PreludeDx’s DCIS testThe US Food and Drug Administration (FDA) has granted breakthrough device designation to PreludeDx's DCISionRT test, a risk assessment tool for ductal carcinoma in situ (DCIS), also known as Stage 0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback